DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial – Yahoo Finance
Montrouge, France, December 23, 2022
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
DBV expects to initiate patient screening in Q1 2023 with the last patient screened by 1H 2024 and topline results anticipated in 1H 2025
Company reiterates that cash on-hand is sufficient to fund operations through VITESSE topline data
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the Company’s VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) Phase 3 clinical trial that will evaluate the modified Viaskin™ Peanut 250 μg patch (DBV712) in peanut-allergic children ages 4 to 7 years. The updated protocol will be submitted to study sites for subsequent Institutional Review Boards (IRB)/Ethics Committees (EC) approval.
In the Partial Clinical Hold (PCH) letter, the FDA requested changes to certain elements of the VITESSE protocol with the intent for the trial to support a Biologics License Application (BLA). The FDA communication contained four protocol modifications: the redefinition of the minimal daily wear time, the addition of a statistical test for the patch adhesion assessment, the reclassification of certain adverse events (AEs) to adverse events of special interest (AESIs) and an increase in the number of trial participants on active treatment.
Key design elements of VITESSE such as inclusion criteria, primary efficacy endpoint, responder criteria, efficacy assessment methodology and safety endpoints were not impacted by the PCH letter and have not changed.
“We are pleased that the FDA has lifted the partial clinical hold on the VITESSE study and anticipate initiating patient screening in Q1 2023,” said Daniel Tassé, Chief Executive Officer of DBV Technologies. “I am proud of our team for continuing to advance important pre-study activities these last several weeks so that we are prepared to act quickly to re-launch VITESSE following today’s announcement.”
Following receipt of the PCH letter, DBV and the FDA discussed how VITESSE protocol modifications could best support the Agency’s review of a potential BLA for Viaskin Peanut as a peanut allergy treatment.
In lifting the PCH, the FDA confirmed DBV satisfactorily addressed all clinical hold issues identified in the PCH letter. The FDA stated that DBV may proceed with VITESSE with the following changes included in the revised protocol:
The updated VITESSE Instructions for Use (IFU) will direct caregivers to apply one patch at approximately the same time each day, following removal of the previous day’s patch. The updated IFU now outlines that Viaskin Peanut 250 µg is to be worn for as close to a full day as possible (i.e., 24 hours) with a minimum daily wear time of 20 hours each day.
Patch adhesion will be assessed in VITESSE to affirm the modified Viaskin Peanut patch performs adequately, which aligns with existing regulatory requirements for patch-based therapies. In post-PCH discussions, DBV and the FDA agreed a statistical test of adhesion will be included in the VITESSE statistical analysis plan and further considered patch adhesion data collection and interpretation in the context of the novel nature of the Viaskin patch platform.
Four AEs will be classified as AESIs. These AEs – which include AEs leading to inhaled or systemic corticosteroid or epinephrine use, systemic allergic reactions, and Grade 4 local application site (skin) reactions – were collected and assessed in all previous Viaskin Peanut trials and included in the previous VITESSE protocol. Only the classification of these AEs has changed.
DBV plans to initiate a separate safety study in approximately 275 additional subjects, randomized 3:1 active versus placebo. The additional safety data generated by this six-month study will supplement the safety data generated by the VITESSE trial, resulting in a safety database comprised of approximately 600 children ages 4 to 7 years treated with Viaskin Peanut. The protocol design of the safety study will be submitted to the FDA and is expected to be similar to the REALISE (REAL Life Use and Safety of EPIT) safety study that DBV previously conducted with Viaskin Peanut in children ages 4 to 11 years.
The Company does not expect the additional safety study to have an impact on the Company’s cash runway guidance as DBV had included a provision for a possible supplemental safety trial in its cash runway assumptions. The Company reiterates that cash on-hand is sufficient to fund operations through VITESSE topline data.
“Following a very productive dialogue with the FDA, we have incorporated the Agency’s modifications to VITESSE into the study protocol and look forward to initiating patient treatments,” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies. “I am confident that the VITESSE study, when completed, will add to the growing body of evidence demonstrating the ability of our novel drug-device immunotherapy platform, Viaskin Peanut, to address significant unmet needs among peanut–allergic children and their families.”
DBV anticipates initiating VITESSE patient screening in the first quarter of 2023 with the last patient screened in 1H 2024 and topline results anticipated in 1H 2025.
About VITESSE
The VITESSE trial will enroll 600 subjects, randomized 2:1 active versus placebo. The study will involve approximately 80 trial sites across the United States, Canada, Australia and Europe. Dr. David Fleischer, Children’s Hospital Colorado, will act as the principal investigator.
The primary efficacy endpoint is the percentage of treatment responders in the active versus placebo arms at Month 12. The primary efficacy analysis includes the success criterion of a lower bound of the confidence interval of the difference in responder rates between active and placebo groups being greater than or equal to 15%.
A treatment responder is defined as either a subject with a baseline eliciting dose (ED) ≤30 mg who reaches an ED ≥300 mg of peanut protein at Month 12, or a subject with a baseline ED = 100 mg who reaches an ED ≥600 mg of peanut protein at Month 12. A double-blind, placebo-controlled food challenge (DBPCFC) will be administered at baseline and Month 12 to determine a subject’s ED at both timepoints.
During the screening period, subjects will undergo an initial visit with assessment for eligibility according to peanut skin prick test (SPT) and serum peanut IgE. Those meeting these criteria will proceed to a DBPCFC to confirm their peanut allergy and establish an entry peanut ED. The entry DBPCFC will be 1 mg peanut protein, and will escalate up to a highest single dose of 100 mg peanut protein. Subjects who react with an ED at or below the dose of 100 mg peanut protein are considered eligible. At Month 12, a post-treatment DBPCFC will be performed, with a starting dose of 3 mg peanut protein, escalating to a highest dose of 1,000 mg peanut protein according to the following schedule: 3, 10, 30, 100, 300, 600, 1,000 mg. Secondary efficacy endpoints include changes in Cumulative Reactive Dose, ED and severity of allergic reaction at Month 12 food challenge.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin™ Peanut as a treatment for peanut-allergic children and the potential benefits of EPIT™, DBV Technologies’ clinical development and regulatory plans, timing and projections of VITESSE study milestones, and timing and anticipated results of interactions with regulatory agencies. All statements about VITESSE study milestones, enrollment and anticipated results contained herein are DBV’s best estimates and projections are based on performance of previous studies and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements with respect to the VITESSE study to differ materially from the estimates and projections contained herein. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties and may be impacted by market conditions as well as other risks and uncertainties set forth in DBV Technologies’ regulatory filings with the Autorité des Marchés Financiers (“AMF”), DBV Technologies’ filings and reports with the U.S. Securities and Exchange Commission (“SEC”) and future filings and reports made with the AMF and SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV Technologies.
Attachment
PDF Version
Related Quotes
iMedia Brands, Inc. (NASDAQ:IMBI) Q3 2022 Earnings Call Transcript November 22, 2022 iMedia Brands, Inc. misses on earnings expectations. Reported EPS is $-0.72 EPS, expectations were $-0.32. Operator: Hello and welcome to iMedia Brands Inc. third quarter 2022 earnings call. At this time, all participants are in a listen-only mode. If anyone should require Operator […]
It's a scary time to be an investor, with the markets languishing and the threat of additional interest rate hikes next year weighing on stock prices. In this environment, it is important to control risk and one way to do that is by investing in quality healthcare companies with consistent, sustainable dividends. Cardinal Health's stock is up more than 60% over the past year.
Another pharmaceutical company is recalling a blood pressure medication that could increase the risk of cancer if taken in large amounts.
CHAPEL HILL, N.C. — The white powder in a small tube arrived one morning by FedEx in a basement office on the campus of the University of North Carolina at Chapel Hill. “Quick OD, half bag, weirdly lethargic after,” the anonymous drug user from Wilmington, North Carolina, wrote on a slip of paper the size of an index card, which came with the tube. The user had a hunch that there was fentanyl in the powder but feared the presence of xylazine, a dangerous animal tranquilizer that can leave oozing
China abruptly ended its "zero-COVID" policies following nationwide protests, but the lack of proper vaccination levels and hospital preparedness left the country vulnerable.
It's been a wild 12 months for biotech company Bluebird Bio (NASDAQ: BLUE). Bluebird earned approval from the U.S. Food and Drug Administration (FDA) for Zynteglo and Skysona in August and September, respectively.
Gummies are especially problematic for kids as they're made to look like candy.
The 82-year-old was admitted to the Hospital Israelita Albert Einstein in Sao Paulo on November 29.
China's Zhejiang, a big industrial province near Shanghai, is battling around a million new daily COVID-19 infections, a number expected to double in the days ahead, the provincial government said on Sunday. Despite a record surge of cases nationwide, China reported no COVID deaths on the mainland for the five days through Saturday, the Chinese Center for Disease Control and Prevention said on Sunday. Citizens and experts have called for more accurate data as infections surged after Beijing made sweeping changes to a zero-COVID policy that had put hundreds of millions of its citizens under relentless lockdowns and battered the world's second-largest economy.
‘Although the number of patients remaining in hospital is low, this is a life-altering incident for all involved’
Could the COVID-19 surge in China unleash a new coronavirus mutant on the world? Every new infection offers a chance for the coronavirus to mutate, and the virus is spreading rapidly in China. Domestic vaccines have proven less effective against serious infection than Western-made messenger RNA versions.
FORT LAUDERDALE, Fla. — She gave birth in secret, perhaps in a hotel bathroom, entirely alone. She was poor or financially dependent, the baby’s father not in the picture. In the months leading up to the birth, she denied she was pregnant, or struggled with a deep ambivalence over what would soon become her fate. Somehow, she kept her entire pregnancy secret from nearly everyone around her, …
The country is meeting the Omicron variant with less exposure to the virus and lower vaccination rates among the elderly.
BEIJING — The hearses bearing black and yellow funeral paper flowers crept in a steady stream toward the Dongjiao crematory in eastern Beijing. Several dozen people crowded around the closed gate waiting to be let in. A man unable to get a spot in line could only watch, wondering what to do with the body of a relative who had just died of COVID-19. The hospital could not keep the body — there were already too many in its morgue. When he called the crematory, an employee told him he had to wait a
Family members spent Christmas morning on Sunday with Pele at the Sao Paulo hospital where the legendary footballer is battling worsening cancer as well as kidney and heart problems, according to a social media post by his daughter.
A California university is apologizing for conducting 'unethical' experiments on thousands of prison inmates that included injecting them with pesticides.
It’s Christmas, we’re all eating more sugar than usual, mulled wine, Quality Street… and thoroughly enjoying it. While these foods give us a lot of pleasure, sugar is also unfortunately damaging to our health. So what can we do in the way of harm reduction? Can we eat our cake and help our body at the same time? We sure can.
Hays police set Jan. 2 court date for terminal cancer patient caught with vape device and edible THC paste.
Mesoblast Limited (NASDAQ:MESO) Q1 2023 Earnings Call Transcript November 23, 2022 Dr. Silviu Itescu: Good morning, good afternoon to the operational highlights and financial results for the quarter ended September 30, 2022, as well as our upcoming Annual General Meeting. Apologies for the slight delay due to technical difficulties; beyond our control. Joining me here […]
Photo Illustration by Erin O'Flynn/The Daily Beast/Getty ImagesAmerican and European corporations have for centuries been bastardizing and profiting from the ceremonial plants and drugs used by Indigenous cultures in the Americas. The most notorious is tobacco, used for sacred purposes across different Indigenous groups like the Seminole and the Navajo for thousands of years in a form that would be unrecognizable to most of us. It was far more concentrated and much harder to inhale. But as Europ